AIM: The analysis of fatal outcomes of @entity3935 in @entity1 with @entity1737 . MATERIAL AND METHODS: The data on 19 @entity1 with myastheniccrisis admitted at the Moscow Regional Research and Clinical Institute (  MONIKI  ) over 12 years (1997-2009) have been summarized. RESULTS AND CONCLUSION: There are more than 600 @entity1 with @entity1737 in the Moscow region, including 13% @entity1 with onset after 60 years. Seventeen @entity1 of 19 were in the intensive care unit. Total @entity204 occurred in 7 cases (36.6%). @entity583 , bilateral @entity55 and @entity548 pulmonary @entity4 caused @entity204 . All @entity1 had concomitant diseases: @entity101 , @entity296 , @entity4854 and others. @entity230 and plasmapheresis were used for treatment of @entity3935 . The authors believe that methods of treatment of @entity3935 that does not lead to complications in elderly age and are suitable for @entity1 with concomitant diseases, who can't be treated with glucocorticoids and plasmapheresis, should be used in clinical neurology. Normal @entity1 intravenous immunoglobulin is recommended in these cases.

[Outcomes and treatment of XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'human'] @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial changes'] @entity3935 :: ('MESH:D013958', 'Disease') :: ['myasthenic crisis'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic'] @entity55 :: ('MESH:D011014', 'Disease') :: ['confluent pneumonia'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity1737 :: ('MESH:D009157', 'Disease') :: ['myasthenia'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['Steroids'] @entity583 :: ('MESH:D009203', 'Disease') :: ['Myocardial infarction'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']
@entity3935 :: (MESH:D013958,Disease) :: ['myasthenic crisis']
